United Therapeutics (NASDAQ:UTHR) Price Target Raised to $466.00

United Therapeutics (NASDAQ:UTHR) had its price target raised by Wells Fargo & Company from $423.00 to $466.00 in a report published on Thursday,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the biotechnology company’s stock.

UTHR has been the subject of a number of other research reports. Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a research report on Wednesday, October 29th. HC Wainwright increased their price objective on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Royal Bank Of Canada lifted their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. Bank of America reiterated a “neutral” rating on shares of United Therapeutics in a report on Wednesday. Finally, TD Cowen raised their price objective on United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research report on Wednesday. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $533.55.

United Therapeutics Stock Up 0.1%

UTHR stock opened at $503.90 on Thursday. The company has a market cap of $22.09 billion, a price-to-earnings ratio of 18.06, a PEG ratio of 1.79 and a beta of 0.85. The business has a fifty day simple moving average of $484.38 and a 200-day simple moving average of $446.93. United Therapeutics has a 52 week low of $266.98 and a 52 week high of $537.19.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The firm had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.19 earnings per share. As a group, analysts expect that United Therapeutics will post 24.48 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO James Edgemond sold 21,000 shares of the stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $479.99, for a total value of $10,079,790.00. Following the completion of the transaction, the chief financial officer owned 8,142 shares of the company’s stock, valued at approximately $3,908,078.58. This represents a 72.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $479.91, for a total value of $10,797,975.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 407,954 shares of company stock worth $197,601,528 in the last quarter. 10.30% of the stock is currently owned by company insiders.

Institutional Trading of United Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in UTHR. Torren Management LLC acquired a new position in United Therapeutics during the 4th quarter worth $26,000. Activest Wealth Management increased its holdings in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the last quarter. Entrust Financial LLC acquired a new stake in United Therapeutics during the fourth quarter valued at approximately $31,000. Wilmington Savings Fund Society FSB lifted its holdings in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares during the last quarter. Finally, Harbor Capital Advisors Inc. bought a new stake in shares of United Therapeutics in the 4th quarter valued at approximately $48,000. Institutional investors own 94.08% of the company’s stock.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q4 outperformance and growth target — UTHR beat EPS expectations (reported strength in Tyvaso DPI sales) and management is targeting roughly a $4B revenue run‑rate by 2027 as several late‑stage product launches approach; this underpins the recent rally and longer‑term growth thesis. Read More.
• Positive Sentiment: Analysts lifting targets — Multiple firms raised price targets (examples: H.C. Wainwright, RBC, Oppenheimer), which supports further upside and institutional interest. Read More.
• Positive Sentiment: Bullish options flow — Unusually large call buying around the print suggests traders are positioning for further upside or volatility in the short term. Read More.
• Neutral Sentiment: Technical/relative strength recognition — UTHR earned a high RS rating (91), signaling market leadership but not guaranteeing direction near term. Read More.
• Neutral Sentiment: Mixed analyst views remain — while many bumped targets, some firms kept Hold/equal‑weight ratings, leaving near‑term consensus mixed. Read More.
• Negative Sentiment: Revenue missed consensus — Q4 revenue came in below Street estimates, which sparked an earlier pullback and is a reminder top‑line execution matters for the multiple. Read More.
• Negative Sentiment: Insider selling — The COO and a director disclosed multi‑lot sales in February (COO sale worth several million and director sales disclosed), which can create investor concern about near‑term insider conviction. Read More. Read More.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.